^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AFM24

    i
    Other names: AFM24, AFM-24
    Company:
    Affimed
    Drug class:
    EGFR inhibitor, CD16A agonist
    Related drugs:
    11ms
    #ASCO23 Abs 2533 📚 ➡️ AFM24 (EGFR & CD16A bispecific innate cell engager) tested in Phase 2a for EGFR mutant #LCSM patients previously treated. 🎯 1 confirmed PR & 4 stable diseases among 10 evaluable pts. 👀 Tumor control rate = 50%. ⚠️ TRAEs reported in 13 pts. Most common:… https://t.co/dvfyFOyRiF (@ADesaiMD)
    Clinical • P2a data
    |
    EGFR (Epidermal growth factor receptor) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    EGFR mutation
    |
    AFM24
    2years
    Keep your eyes, Dr, Ueno, on affimed's solid tumor engager targeting egfr: AMF 24. 3 trials (9 arms) enrolling now; topline data 2H 2022. Interestingly, in contrast/as a complement to the MDA AMF13/cb-nk approach, the nk combo arm w/AFM 24 is using autologous NK's . . . (@zen_tropy)
    EGFR (Epidermal growth factor receptor)
    |
    AFM24